ATOS

Atossa Therapeutics, Inc.

1.13 USD
-0.02 (-1.74%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Atossa Therapeutics, Inc. stock is down -29.38% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 58.33% of the previous 11 June’s closed higher than May. 100% of analysts rate it a buy.

About Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxefen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized patients.